Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6291.

https://doi.org/10.1182/blood-2024-203317

Published: 2024

Journal Articles

A Canadian Cost-Utility Analysis of Epcoritamab Versus Current Therapies in Third-Line or Later Large B-Cell Lymphoma

Shivani Kamdar, David Macdonald, Athina Palaka, Angelina Addae, Colin Vicente, Anthony W Wang, Dipti Tankala, Stephane Barakat

Blood (2024) 144 (Supplement 1): 7617.

https://doi.org/10.1182/blood-2024-210199

Published: 2024

Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons

Blood (2023) 142 (Supplement 1): 3037.

https://doi.org/10.1182/blood-2023-186347

Published: 2023

Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche

Blood (2022) 140 (Supplement 1): 9383–9384.

https://doi.org/10.1182/blood-2022-169245

Published: 2022

Journal Articles

Does Upfront Autologous Stem Cell Transplant at First Relapse Improve Outcome in Transplant Eligible Follicular Lymphoma Patients Who Relapse within 24 Months

Ayel Omar Q Yahya, MD, David MacDonald, MD, Osman Radhwi, MD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-134622

Published: 2020

Journal Articles

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Judith Trotman, FRACP, Christian Buske, MD, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David MacDonald, MD, Constantine Tam, MBBS, Olivier Tournilhac, MD PhD, Shuo Ma, MD PhD, Steven P. Treon, MD PhD, Albert Oriol, Jerry Ping, PhD, Eva M. Briso, PhD, Israel Arango-Hisijara, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-133916

Published: 2020

Journal Articles

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-134460

Published: 2020

Journal Articles

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Mathias J Rummel, MD PhD, Ann Janssens, David MacDonald, MD FRCPC, Mary-Margaret Keating, MD, Jan Zaucha, MD, Jaclyn Davis, MD, Janet Lasher, Nathalie Lobe, Miguel Izquierdo, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 450.

https://doi.org/10.1182/blood-2018-99-114484

Published: 2018

Journal Articles

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Christian Buske, MD, Alessandra Tedeschi, MD, Judith Trotman, FRACP, Ramon García-Sanz, MD PhD, David MacDonald, MD, Véronique Leblond, MD PhD, Beatrice Mahe, MD, Charles Herbaux, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, M. Lia Palomba, MD, Jeffrey V Matous, MD, Chaim Shustik, MD, Eftathios Kastritis, MD, Steven P Treon, MD PhD FRCP, Chih-Jian Lih, PhD, Jianling Li, MS, Zeena Salman, BS, Thorsten Graef, MD PhD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 149.

https://doi.org/10.1182/blood-2018-99-111178

Published: 2018

Journal Articles

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Brad S Kahl, MD, John M. Burke, MD, Richard van der Jagt, MD FRCPC, Julie Chang, MD, Peter Wood, Tim Hawkins, FRACP, FRCPA, David MacDonald, Judith Trotman, MBChB, FRACP, FRCPA, David Simpson, MBChB, Kathryn S. Kolibaba, MD, Samar Issa, FRACP, Doreen Hallman, Ling Chen, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 484.

https://doi.org/10.1182/blood.V130.Suppl_1.484.484

Published: 2017

Journal Articles

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Andrew J Davies, FRCP PhD, Biljana Mihaljevic, Santiago Mercadal, MD, Georgi Mihaylov, Sirpa Leppä, Denise Cotting, Klaas Veenstra, Artem Zharkov, Mark Dixon, BSc MSC, Martin Barrett, David Macdonald

Blood (2016) 128 (22): 1103.

https://doi.org/10.1182/blood.V128.22.1103.1103

Published: 2016

Journal Articles

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Blood (2016) 128 (2): 185–194.

https://doi.org/10.1182/blood-2016-02-699520

Published: 2016

Includes: Supplemental data

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Sarit Assouline, Michael Crump, MD, Torsten Holm Nielsen, Miguel Alcaide, B. Sc., Ph. D., David Macdonald, MD FRCPC, Axel Tosikyan, Tina Haliotis, Celia Greenwood, Kathleen Klein Oros, Ryan Morin, PhD, Nathalie Johnson, MD PhD, Koren Kathleen Mann, PhD

Blood (2015) 126 (23): 2719.

https://doi.org/10.1182/blood.V126.23.2719.2719

Published: 2015

Journal Articles

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Peter Wood, Tim E. Hawkins, David MacDonald, Mark Hertzberg, Yiu-Lam Kwan, David Simpson, Michael Craig, Kathryn Kolibaba, Samar Issa, Regina Clementi, Doreen M. Hallman, Mihaela Munteanu, Ling Chen, John M. Burke

Blood (2014) 123 (19): 2944–2952.

https://doi.org/10.1182/blood-2013-11-531327

Published: 2014

Includes: Supplemental data

Journal Articles

Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)

Andrew Davies, MD, Francesco Merli, Biljana Mihaljevik, Noppadol Siritanaratkul, MD, Philippe Solal-Céligny, MD, Axel Boehnke, Claude Berge, Christine McIntyre, Martin Barrett, PhD, David Macdonald, MD, FRCPC

Blood (2012) 120 (21): 1629.

https://doi.org/10.1182/blood.V120.21.1629.1629

Published: 2012

Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 155.

https://doi.org/10.1182/blood.V120.21.155.155

Published: 2012

Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD

Blood (2012) 120 (21): 902.

https://doi.org/10.1182/blood.V120.21.902.902

Published: 2012

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC

Blood (2011) 118 (21): 1605.

https://doi.org/10.1182/blood.V118.21.1605.1605

Published: 2011

NARROW

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

A Canadian Cost-Utility Analysis of Epcoritamab Versus Current Therapies in Third-Line or Later Large B-Cell Lymphoma

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Does Upfront Autologous Stem Cell Transplant at First Relapse Improve Outcome in Transplant Eligible Follicular Lymphoma Patients Who Relapse within 24 Months

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE TM Trial

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE TM Study

Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATE TM Study

Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial

Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only